On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns ...

BTIG analysts have downgraded Globus Medical from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

Zimmer Biomet announced today that it appointed Kevin Thornal as group president, global businesses and the Americas.

Thornal will join the orthopedics company as group president for global businesses and the Americas, a newly created position.

Zimmer Biomet named Kevin Thornal as group president for global business and the Americas, according to a May 27 news release. Mr. Thornal will join the company July 1. He was previously CEO and ...

Globus Medical seems to be reverting to form, reporting a big jump in operating profit and profit margin for Q1, 2025. Here ...

From new partnerships and launches, here are six developments from Globus Medical so far in 2025. 1. OsteoCentric Technologies entered into a non-exclusive licensing agreement with Globus Medical.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED).

Wittes covers the Healthcare sector, focusing on stocks such as Globus Medical, Allurion Technologies, and Monogram Orthopaedics Inc. According to TipRanks, Wittes has an average return of 3.6% ...

Scavilla confirmed the acquisition of Nevro Corporation for $250 million, expanding Globus Medical's reach into the musculoskeletal market, particularly in neuromodulation technology and chronic ...